Sierra Summit Advisors LLC Has $687,000 Holdings in Hims & Hers Health, Inc. $HIMS

Sierra Summit Advisors LLC reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 23.5% in the 2nd quarter, HoldingsChannel reports. The firm owned 13,787 shares of the company’s stock after selling 4,239 shares during the period. Sierra Summit Advisors LLC’s holdings in Hims & Hers Health were worth $687,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Quaker Wealth Management LLC bought a new stake in shares of Hims & Hers Health during the 2nd quarter worth $29,000. Bessemer Group Inc. lifted its stake in Hims & Hers Health by 105.8% in the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the period. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health during the first quarter worth $30,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Hims & Hers Health in the 1st quarter valued at about $41,000. Finally, Spire Wealth Management acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $42,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Trading Up 3.2%

Shares of HIMS stock opened at $34.71 on Monday. Hims & Hers Health, Inc. has a 1 year low of $23.03 and a 1 year high of $72.98. The firm has a fifty day moving average price of $49.10 and a 200-day moving average price of $51.14. The company has a market cap of $7.90 billion, a price-to-earnings ratio of 64.28, a PEG ratio of 6.91 and a beta of 2.20. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The firm had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the prior year, the company posted $0.32 earnings per share. The company’s revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has authorized a stock buyback plan on Monday, November 17th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts have recently commented on HIMS shares. Truist Financial lowered their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Bank of America lifted their target price on Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. UBS Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, November 4th. BTIG Research restated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a research report on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $45.27.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at $7,139,264.40. This represents a 52.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Michael Chi sold 13,749 shares of the stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $50.50, for a total transaction of $694,324.50. Following the sale, the insider directly owned 297,139 shares of the company’s stock, valued at approximately $15,005,519.50. This trade represents a 4.42% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 628,012 shares of company stock worth $33,430,456 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.